Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

1564 - Long-term Results of Phase 2 Trial of Reduced Modified Clinical Target Volume in Low-risk Nasopharyngeal Carcinoma Treated with Intensity Modulated Radiotherapy


30 Sep 2019


Poster Display session 3


Tumour Site

Head and Neck Cancers


Jingjing Miao


Annals of Oncology (2019) 30 (suppl_5): v449-v474. 10.1093/annonc/mdz252


J. Miao1, M. Di2, Y. Cao3, L. Wang2, W. Xiao1, M. Zhu2, B. Chen2, S. Huang1, F. Han1, X. Deng1, Y. Xiang2, M.L.K. Chua4, X. Guo5, C. Zhao2

Author affiliations

  • 1 Department Of Radiation Oncology, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN
  • 2 Department Of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN
  • 3 Department Of Oncology, First Affiliated Hospital of Guangdong Pharmaceutical University, 510060 - Guangzhou/CN
  • 4 Division Of Radiation Oncology; Division Of Medical Sciences; Oncology Academic Programme, National Cancer Centre Singapore; Duke-NUS Medical School, 169610 - Singapore/SG
  • 5 Nasopharynx, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1564


Intensity modulated radiation therapy (IMRT) is the standard of care for nasopharyngeal carcinoma (NPC). Part of the IMRT quality assurance process involves accurate target volume delineation, which is crucial for local control and survival. Current practice utilizes a uniform contouring method for clinical target volume (CTV) for all stages of NPC. Here, we conducted a single-arm phase 2 trial investigating the tumor control rates of reduced CTV margins and corresponding doses in low-risk, early-stage NPC.


Patients with biopsy-proven stage I-IIb (6th UICC/AJCC) NPC were enrolled. All patients were treated with IMRT alone. Two CTVs (CTV1 [high risk] and CTV2 [low risk]) were outlined; CTV1 was defined by grossly identified tumour (on MRI or CT) plus 5-mm margin (3-mm posteriorly); CTV2 was CTV1 plus 5-mm margin (3-mm posteriorly). 60 Gy and 50–54 Gy in 30 fractions were prescribed to CTV1 and CTV2, respectively. Primary end-point was locoregional recurrence free survival (LRRFS).


From May 2001 to August 2006, 103 patients were recruited; all patients completed IMRT as planned (time duration 39-61 days). At a median follow-up of 12.6 years, five patients developed locoregional failures; of which one was in-field, and four were regional recurrence (two in-field and two marginal). 10-year LRRFS, distant metastasis free survival (DMFS), disease specific survival (DSS) and overall survival (OS) were 95.0% and 94.1%, 94.0% and 91.1%, respectively. The most common grade 1-2 late toxicities included subcutaneous fibrosis (79.6%), hearing loss (53.4%) and skin dystrophy (43.2%); grade 3 included subcutaneous fibrosis (2.9%) and hearing loss (2.9%); and no grade 4 late toxicity.


Reduced CTV margins and corresponding doses results in optimal long-term tumour control, with minimal late adverse events.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Chong Zhao.


National Natural Science Foundation of China [No. 81872469]; Science and Technology Project of Guangdong Province [No. 2014A020212433].


M.L.K. Chua: Honoraria (institution), Advisory / Consultancy: Janssen, Astellas, Varian, Ferring Singapore and AstraZeneca; Research grant / Funding (institution), Structured research agreement/Research funding - Ferring Singapore, GenomeDx Biosciences, Varian, MedLever.: Ferring Singapore, GenomeDx Biosciences, Varian, MedLever. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.